Skip to content
Biotechnology, Finance Investment

Humanitech Lab scales up support to aid innovation

Australian Red Cross 2 mins read

Australian Red Cross is thrilled to announce a significant milestone in its mission to leverage cutting-edge technology to address critical humanitarian and social issues. Two innovative startups from the Humanitech Lab’s pilot phase, Kara Technologies and AirSeed, have been selected as recipients of scale-up funding, with support from founding partner Telstra Foundation.

In a joint effort to drive positive change and align with the core work of Australian Red Cross in inclusion, preparedness, resilience, and recovery, the organisations have been awarded a grant of $500,000 to enable them to expand their groundbreaking projects and champion innovation in Australian communities.

Kara Technologies, known for its dedication to inclusivity and accessibility-focused innovation, is set to make a significant impact with the Australian Deaf Community.

Head of Humanitech Katy Southall said the startup has received funding to increase access to sign language in preparedness and emergency situations using "digital human" avatars and motion capture technology.

“After piloting this groundbreaking technology alongside Deaf Communities and Australian Red Cross’ Emergency Services team, the funds will bolster efforts to provide Emergency preparedness activities in fast and on-demand Auslan (Australian Sign Language) to ensure the Deaf Community can access crucial support when it matters most,” said Ms Southall.

AirSeed is an initiative that harnesses drone and bio-technology to regenerate land at scale across Australia. With the funding and the support of Australian Red Cross’ Emergency Services team, AirSeed is sowing the seeds of change through its game-changing approach to revegetate land in flood-affected communities.

“This initiative enhances both the climate and psychosocial resilience of communities facing environmental challenges, as the organisation looks to shape the future resilience of disaster affected communities through rapid revegetation in Australia and around the globe.”

Ms Southall reiterated that the Humanitech Lab investments underscore Australian Red Cross’ unwavering commitment to using innovation in addressing the most pressing challenges faced by Australian communities.

“Through organisations like Kara Technologies and AirSeed, Australian Red Cross is using the Humanitech lab to support the use of technology to make a meaningful impact,” said Ms Southall.

To read more on the Lab and other forward-thinking start-ups visit https://www.humanitech.org.au/.


Contact details:

Media inquiries: media@redcross.org.au or 1800 733 443

More from this category

  • Finance Investment
  • 06/09/2024
  • 20:40
Hut 8 Corp.

Hut 8 Operations Update for August 2024

18.5 EH/s and 762 MW under management in miningEnergized Building 1 at CedarvaleMIAMI, Sept. 06, 2024 (GLOBE NEWSWIRE) -- Hut 8 Corp. (Nasdaq | TSX: HUT) (“Hut 8” or the “Company”), a leading, vertically integrated operator of large-scale energy infrastructure and one of North America’s largest Bitcoin miners, today released its operations update for August 2024.“During August, we maintained our focus on low-cost operations and unit economics,” said Asher Genoot, CEO of Hut 8. “Maximizing returns from our current fleet remains a priority while we continue to plan a thoughtfully structured fleet upgrade to next-generation ASICs. Reactor, our curtailment software, enabled…

  • Finance Investment, Government Federal
  • 06/09/2024
  • 18:34
The professional bodies representing Australia's tax and BAS agents

JOINT BODIES REMAIN CONCERNED ABOUT NEW TAX AGENT OBLIGATIONS AFTER ROUNDTABLE

6 September 2024 The professional bodies representing Australia’s tax and BAS agents met with the Assistant Treasurer’s office and Treasury today to discuss our ongoing concerns regarding the Tax Agent Services (Code of Professional Conduct) Determination 2024. The Assistant Treasurer’s office and Treasury acknowledged our concerns with sections 15 and 45 of the Determination and we are pleased they are open to making the necessary changes to address them. However, there is still considerable work to be done and further consultation required. The joint bodies* made it clear today that the proposed amendments will still make our members’ work challenging,…

  • Contains:
  • Biotechnology
  • 06/09/2024
  • 12:00
Cleo Diagnostics Limited. ASX.COV

Cleo Commences U.S. Clinical Trials for its Ovarian Cancer Diagnostic Blood Test

Highlights U.S. clinical trials commenced with first patients enrolled over 8 recruitment centres Trial will validate the use ofCLEO’s ovarian cancer blood test for the U.S. market Pathway set toward FDA submission in CY2025. ___________ MELBOURNE, AUSTRALIA, 6 September 2024: Ovarian cancer diagnostics company, Cleo Diagnostics Limited (ASX:COV) (CLEO, or the Company) is pleased to confirm the commencement of U.S. clinical trials for its ovarian cancer diagnostic blood test. Commencement of U.S. Clinical Trials CLEO’s pivotal FDA-enabling clinical trial has commenced in the United States, with first patients recruited into the study. The trial is designed to benchmarkCLEO’s technology, with…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.